Monopar Therapeutics Inc. (MNPR) Total Assets by Year
Monopar Therapeutics Inc. closed fiscal year 2025 with $140.7M in total assets, $2.9M in total liabilities and $137.8M in shareholder equity. This represents an increase of 133.4% from the prior fiscal year. The table below carries 10 fiscal years, from 2016 to 2025, and the quarters Monopar Therapeutics Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
MNPR Balance Sheet by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY23DEF 14A | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $140.7M+133.4% | $60.3M+720.8% | $7.3M-44.5% | $13.2M-35.5% | $20.5M+21.7% | $16.9M+26.3% | $13.4M+82.5% | $7.3M-26.3% | $9.9M+243.0% | $2.9M |
| Total Liabilities | $2.9M-45.0% | $5.3M+199.0% | $1.8M-44.0% | $3.1M+98.5% | $1.6M+34.3% | $1.2M+62.5% | $724K+81.2% | $400K+28.1% | $312K+383.4% | $65K |
| Total Equity | $137.8M+150.4% | $55.0M+885.0% | $5.6M-44.6% | $10.1M-46.7% | $18.9M+20.7% | $15.7M+24.3% | $12.6M+82.5% | $6.9M-28.1% | $9.6M+239.8% | $2.8M |
MNPR Balance Sheet by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $135.0M+150.6% | $138.0M+150.5% | $140.7M+133.4% | $144.2M+2275.7% | $53.9M+650.2% | $55.1M+518.1% | $60.3M+720.8% | $6.1M-29.4% | $7.2M-30.6% | $8.9M-24.7% | $7.3M-44.5% | $8.6M-40.5% |
| Total Liabilities | $4.1M+147.8% | $2.6M+73.6% | $2.9M-45.0% | $2.6M+135.1% | $1.7M+52.7% | $1.5M+4.0% | $5.3M+199.0% | $1.1M-43.3% | $1.1M-56.5% | $1.4M-50.3% | $1.8M-44.0% | $2.0M+2.4% |
| Total Equity | $130.9M+150.7% | $135.4M+152.6% | $137.8M+150.4% | $141.6M+2761.6% | $52.2M+757.1% | $53.6M+616.8% | $55.0M+885.0% | $4.9M-25.2% | $6.1M-22.3% | $7.5M-16.4% | $5.6M-44.6% | $6.6M-47.2% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More Monopar Therapeutics Inc. financials
Frequently Asked Questions
What was Monopar Therapeutics Inc.'s total assets in fiscal year 2025?
Monopar Therapeutics Inc. closed fiscal year 2025 with $140.7M in total assets, $2.9M in total liabilities and $137.8M in shareholder equity.
How fast is Monopar Therapeutics Inc.'s total assets growing?
Monopar Therapeutics Inc. (MNPR) total assets rose by 133.4% year over year, from $60.3M to $140.7M in fiscal year 2025.
How has Monopar Therapeutics Inc.'s total assets changed over the years?
Across the 10 fiscal years this page covers, Monopar Therapeutics Inc. (MNPR) total assets went from $2.9M in fiscal year 2016 to $140.7M in fiscal year 2025.
What was Monopar Therapeutics Inc.'s total assets in the most recent quarter?
Monopar Therapeutics Inc. (MNPR) reported $135.0M in total assets in Q2 2026. This represents an increase of 150.6% from the same quarter a year earlier.
What does total assets mean on a financial statement?
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Monopar Therapeutics Inc. (MNPR) reported on that line in every period on record.